The purpose of this symposium is to update medical practitioners in the greater Midwest region on the future of cardiac electrophysiology.
Search for "" returned 68 matches
This course is designed to provide the learner with the most up to date review of lead management.
This meeting will cover the broad spectrum of endeavors in the field of arrhythmia and device management
The Transvenous vs Subcutaneous ICD: Which Patients for Which Device? Pre-operative and Post-operative Considerations (Activity Expired)18332
This 50 minute three-part webinar contrasts the transvenous ICDs to the novel subcutaneous ICD with regards to patient screening, surgical implant technique, and post - operative concerns.
This activity is centered around heart rhythm management and implantable device management.
WASHINGTON, DC — The U.S. Food and Drug Administration, in collaboration with major implantable pacemaker and ICD manufacturers, demonstrated the effects of emissions from radio frequency identification (RFID) readers on common implantable cardiac devices. According to research published in the January edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, the observed effects may cause increasing complications as RFID use expands in the medical device field.
WASHINGTON, DC — March 1, 2010 – Analysis of ICD patients enrolled in four different trials found patients with life-threatening ventricular arrhythmias (VA) treated only with antitachycardia pacing (ATP) have higher survival rates than VA patients who experienced at least one shock-treated episode. According to research published in the March edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, 80.2% of VA episodes were successfully treated with ATP-only therapy from an ICD.
DENVER, May 13, 2010 – According to a sub-study of the Multicenter Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT), females receive a clinically significant benefit from cardiac resynchronization therapy devices (CRT-D) compared to men. New research presented today at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions, indicates that CRT-D therapy reduces all-cause mortality and heart failure (HF) and death end point in females, but not in males.
This symposium will address the compelling evidence for aggressive medical and device-based therapies for patients with chronic heart failure. The overall goal is the integration of medical, device, diagnostic and surgical therapies for our patients with chronic heart failure.
WASHINGTON, July 1, 2010 — New large meta-analysis from five primary prevention randomized implantable cardioverter-defibrillator (ICD) studies shows a smaller impact of Sudden Cardiac Death (SCD) on overall mortality in women. According to research published in the July edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, women in primary prevention ICD trials have the same overall mortality as men, while experiencing significantly less appropriate ICD interventions. With more than 1,600 women, this meta-analysis includes the largest cohort of women to date.